|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2005-9-16
|
|
pubmed:abstractText |
Saccadic eye velocity (SEV) has been shown to be a reliable neurophysiological tool for the assessment of gamma-aminobutyric acid GABA(A) receptor sensitivity. Administration of benzodiazepines targeting the GABA(A) receptor decreases SEV in healthy volunteers. Tiagabine is a new antiepileptic drug which acts via selective blockade of GABA reuptake. Therefore, we examined the effects of tiagabine on saccade parameters.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0302-282X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright (c) 2005 S. Karger AG, Basel.
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
52
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
147-50
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Saccadic eye velocity after selective GABAergic treatment with tiagabine in healthy volunteers.
|
|
pubmed:affiliation |
Department of Psychiatry, University of Munich, Nussbaumstrasse 7, DE-80336 Munich, Germany. zwanzger@med.uni-muenchen.de
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
